US Patent

US11844788 — Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

Formulation · Assigned to Deciphera Pharmaceuticals LLC · Expires 2040-12-30 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

Deciphera Pharmaceuticals LLC has patented low-impurity compositions of a compound useful in treating disorders related to the c-KIT and PDGFRα kinases.

USPTO Abstract

Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRÎ± kinases, and oncogenic forms thereof.

Drugs covered by this patent

Patent Metadata

Patent number: US11844788
Jurisdiction: US
Classification: Formulation
Expires: 2040-12-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.